CYTARABINE + Cladribine + Azacitidine + Venetoclax for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 May 2022: Trial registered, NCT05365035
  2. 23 Sep 2022: Trial started, NCT05365035

The trials

NCT05365035: A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

State
Under way
Phase
Phase 2
People
60 planned
Started
23 Sep 2022
Primary completion
31 Dec 2027
Arms
cladribine, cytarabine, venetoclax, and azacitidine
Results
None posted
  1. 6 May 2022: Trial registered
  2. 23 Sep 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.